Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 25, 2018
Targets & Mechanisms

Blueprint for selectivity

Why Blueprint thinks its selective ALK2 inhibition is the best bet for treating FOP
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

BioCentury | May 15, 2014
Distillery Therapeutics

Indication: Cancer

BioCentury | Apr 3, 2014
Targets & Mechanisms

Narrowing down graft stenosis

BioCentury | Jun 18, 2009
Distillery Therapeutics

Indication: Neurology

Items per page:
1 - 6 of 6